India Medical Devices Market Report 2026: CDSCO MDR 2017, PLI Manufacturing, and Commercial Intelligence

The Indian medical devices market is estimated at USD 11–14 billion in 2026, growing at approximately 8% CAGR — among the fastest rates globally. India's medical device market is the fourth-largest in Asia, driven by expanding hospital infrastructure, Ayushman Bharat insurance coverage, and government-led healthcare investment. Approximately 75–80% of India's advanced medical device demand is met by imports (predominantly from the US, Germany, Japan, and China), creating significant opportunity for both international manufacturers and India's growing domestic medtech industry. The government's Production Linked Incentive (PLI) scheme for medical devices is stimulating domestic manufacturing of priority device categories.

India's Medical Devices Rules, 2017 (MDR 2017) brought all medical devices under CDSCO (Central Drugs Standard Control Organisation) regulation for the first time, replacing the earlier partial coverage under the Drugs and Cosmetics Act. Devices are classified Class A (lowest risk), B, C, and D (highest risk). Class A and B devices require registration; Class C and D require CDSCO approval with technical dossier review. Manufacturing licences are issued by State Licensing Authorities (SLAs); import licences are issued centrally by CDSCO. The Sugam online portal manages device registration applications. CDSCO has published notified device categories expanded progressively since 2017 — not all device categories are fully notified yet under MDR 2017. Import devices with CE/FDA clearance benefit from an abridged review process.

The Production Linked Incentive (PLI) scheme for medical devices, launched by the Government of India in 2020, provides financial incentives of 5% on incremental sales for 5 years for domestic manufacturers of targeted device categories. PLI target segments include: cancer care/radiotherapy devices; radiology and imaging equipment; anaesthesia and cardiology devices; and all implants. The PLI scheme aims to reduce India's import dependency (currently ~75%) and position India as a global medical device manufacturing hub. Companies like Wipro GE Healthcare, L&T, Trivitron Healthcare, and Skanray Technologies are among the PLI beneficiaries. India's four Medical Device Parks (in Andhra Pradesh, Telangana, Tamil Nadu, Himachal Pradesh) provide shared infrastructure for device manufacturers.

The five largest Indian medical device segments by value are: consumables and disposables (surgical gloves, syringes, IV catheters, wound care — largest by volume, largely domestic manufacturing); diagnostic imaging (CT, MRI, ultrasound — predominantly imported; large installed base in metro hospitals); in vitro diagnostics (laboratory analysers and rapid diagnostic tests — significant domestic manufacturing strength); cardiovascular devices (stents, pacemakers, cardiac monitoring — government price regulation on coronary stents created significant commercial disruption); and orthopaedics (joint replacement, spinal devices — import-dominant but domestic manufacturing growing). Digital health and telemedicine platforms are a fast-growing emerging segment.

India's NPPA (National Pharmaceutical Pricing Authority) extended its price control mandate to medical devices following the 2017 coronary stent price cap — one of the most significant government interventions in a device category globally. Coronary stents were capped at INR 7,260–27,890 (a reduction of 60–80% from pre-cap prices). Knee implants were also price-capped in 2017. The NPPA price control framework creates significant commercial risk for device categories that may become subject to pricing regulation. AMTZ (Andhra Pradesh MedTech Zone) and BioAsia engage with international device manufacturers to establish local manufacturing partnerships that may provide greater commercial flexibility under the PLI and price control frameworks.

BioNixus delivers medical device market research in India: regulator-aware access intelligence, hospital consumption analogues, physician and payer qualitative programmes, and launch evidence under EphMRA and BHBIA governance with GDPR-aligned fieldwork for multinational sponsors. Teams receive decision-ready outputs validated against national policy and institution-level adoption—not desk extrapolation from unrelated regions.

BioNixus supports India-based medical device companies expanding into GCC and MENA markets with SFDA and MOHAP regulatory intelligence, NUPCO and hospital procurement tracking in Saudi Arabia, UAE insurer and formulary research, physician panels across GCC countries, and comparative India versus GCC market intelligence. GCC expansion is a distinct service line with its own tender and access calendars—see our GCC pharmaceutical market report for regional context. Launch assumptions should be validated market by market rather than from a single Gulf average.